Speech Treatment for Minimally Verbal Children With ASD and CAS

Autism Spectrum Disorder Clinical Trial

— TxMVASD+CAS  

Official title:

Speech Treatment for Minimally Verbal Children With ASD and CAS

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05066178
• Other study ID #: 2021P002598
• Status: Recruiting
• Phase: N/A
• Start date: May 1, 2024
• Est. completion date: November 30, 2024

Study information

• Verified date: March 2024
• Source: MGH Institute of Health Professions
• Contact: Karen V Chenausky, Ph.D.
• Phone: 617-726-2405
• Email: kvchenausky[@]mghihp.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.

Description:

Although one in four children with autism remain minimally verbal past age five, not all the factors that limit spoken language in these minimally verbal children are known. One powerful contributor may be a motor speech disorder, Childhood Apraxia of Speech (CAS). CAS is an impairment in the ability to plan and sequence for speech, which makes speech inconsistent and imprecise. This project proposes to investigate whether CAS makes the speech of minimally verbal children with autism unintelligible, and then to test whether treating the CAS improves children's speech. First, a cohort of 20 minimally verbal children with both autism and CAS is identified. The prediction is that the more severe the CAS, the more inconsistent and imprecise a child's speech, and therefore the lower their intelligibility will be. Then, a set of mono- and bisyllabic words is selected that contain the disordered movements that each child shows and use those in treatment. Treatment will take the form of 15 one-hour sessions where speech practice is embedded in a naturalistic, play-based milieu that is centered on each child's own developmental level. It will involve principles of motor learning (intensive practice of a few words, sometimes all in a row and sometimes mixed up). Different types of cues (touch cues, simultaneous production, etc.) will also be employed to help children say their words correctly, fading back these supports as the child's speech improves. Both of these techniques have been shown to be effective for treating CAS. Our outcome measures will include both (1) "by-ear" assessments of intelligibility and (2) acoustic and kinematic measurements of children's speech after 15 treatment sessions. The findings will inform clinical practice for minimally verbal children with autism and may lead to the development of novel interventions for this severely affected population.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: November 30, 2024
• Est. primary completion date: November 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 18 Years

Eligibility

Inclusion Criteria:

• Meets criteria for Autism Spectrum Disorder
• Able to correctly repeat at least 2 syllables
• Meets criteria for Childhood Apraxia of Speech
• Lives in an environment where child is exposed to English at least 50% of the time

Exclusion Criteria:

• Poorly controlled seizures
• Factors such as blindness or deafness that contribute to minimally verbal status
• Lives in an environment where English is not spoken at least 50% of the time
• Child experiences behavioral challenges that preclude participation in the study

Related Conditions & MeSH terms

• Apraxias
• Autism Spectrum Disorder
• Developmental Verbal Dyspraxia

Intervention

Behavioral:
• CAS Treatment for Minimally Verbal Children with Autism
Treatment involves principles of motor learning embedded in a naturalistic developmental milieu

Locations

Country	Name	City	State
United States	MGH Institute of Health Professions	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
MGH Institute of Health Professions

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Attempts Correct	Number or percent of target items that were produced correctly	5 weeks
Primary	Phonemes Correct	Number or percent of phonemes (vowels, consonants) in the target items that were produced correctly	5 weeks
Secondary	Lip aperture movement variability	Amount of variability in lip opening area during production of multiple attempts at the same target	5 weeks
Secondary	Phoneme distinctiveness	Acoustic distinctiveness of different phonemes	5 weeks